Research and Application Progress of SHPS1 Recombinant Protein

 Preparation Technology of SHPS1 Recombinant Protein

SHPS1 recombinant protein is a protein product obtained by introducing the SHPS1 gene into an expression system through genetic engineering technology and then purifying it. With advancements in molecular biology techniques, there are now multiple mature methods to efficiently prepare bioactive SHPS1 recombinant protein. The most commonly used expression systems include mammalian cell expression systems (such as HEK293 and CHO cells), insect cell expression systems (such as Sf9 cells), and prokaryotic expression systems (such as E. coli). Each system has its own advantages and disadvantages. Mammalian cell expression systems can provide post-translational modifications closest to the natural state, particularly glycosylation, which is especially important for SHPS1, a highly glycosylated membrane protein. In contrast, prokaryotic expression systems, while cost-effective and easy to operate, cannot achieve correct glycosylation modifications and are typically only used to prepare specific functional domain fragments of SHPS1.

During the preparation process, researchers need to pay special attention to several key technical steps. The first is the design of the expression vector. Specific tag sequences, such as His tags, FLAG tags, or Fc fusion tags, are often added to the N-terminus or C-terminus of the SHPS1 gene. These tags not only facilitate subsequent purification steps but can also be used for detection and functional studies. The second step is the transfection and screening process. For mammalian cell systems, transfection conditions need to be optimized to obtain high-expression cell lines, while for the establishment of stable cell lines, antibiotic screening and monoclonal screening are required. The final step is the purification process. Since SHPS1 is a membrane protein, its purification process is relatively complex. Detergents (such as Triton X-100 or DDM) are typically used to solubilize the protein from membrane components, followed by affinity chromatography (such as Ni-NTA columns for His-tagged proteins) and size-exclusion chromatography to obtain high-purity protein.

In recent years, with the development of protein engineering technology, various improved versions of SHPS1 recombinant protein have been developed. For example, phosphorylation site mutants obtained through site-directed mutagenesis can be used to study the role of specific tyrosine residues in signal transduction. Glycoengineered SHPS1 proteins with uniform glycosylation patterns help investigate the impact of glycosylation on its function. Truncated SHPS1 extracellular domain proteins are more amenable to crystallization and are widely used in structural biology research. These technological advancements have provided powerful tools for the functional study and application development of SHPS1.

Quality Control and Characterization of SHPS1 Recombinant Protein

To ensure the reliability and experimental reproducibility of SHPS1 recombinant protein research, establishing strict quality control standards is crucial. A comprehensive quality control system typically includes purity analysis, molecular weight determination, secondary structure identification, bioactivity detection, and stability evaluation. Purity analysis is primarily conducted through SDS-PAGE electrophoresis and high-performance liquid chromatography (HPLC). High-quality SHPS1 recombinant protein should achieve a purity of over 95%, with electrophoresis results showing a single main band and no significant protein degradation or impurity bands. Molecular weight determination is performed using mass spectrometry, which can confirm the accurate molecular weight of the protein and detect post-translational modifications, such as glycosylation and phosphorylation.

For the structural characterization of SHPS1 recombinant protein, circular dichroism (CD) is a conventional method for analyzing its secondary structure composition and assessing whether the protein maintains the correct folded state. More advanced techniques, such as nuclear magnetic resonance (NMR) and X-ray crystallography, can provide three-dimensional structural information at the atomic level. Although these methods have high sample requirements and technical difficulties, they are essential for a deeper understanding of the structure-function relationship of SHPS1. Notably, recent breakthroughs in cryo-electron microscopy (cryo-EM) have made membrane protein structure determination more convenient. Some research teams have successfully used this technology to resolve the high-resolution structure of the full-length SHPS1-CD47 complex.

Bioactivity detection is a core aspect of quality control for SHPS1 recombinant protein. Depending on the research objectives, various methods can be used to evaluate its functional activity. The most common methods include surface plasmon resonance (SPR) to measure its binding affinity with CD47, in vitro phosphorylation assays to detect its ability as a substrate for SHP-1/SHP-2, and cell experiments to verify its regulatory role in macrophage phagocytosis. It is worth noting that SHPS1 recombinant protein from different batches may exhibit variations in bioactivity, making it necessary to establish standardized activity measurement methods and reference standards.

Stability studies focus on the preservation performance of SHPS1 recombinant protein under various conditions. Conventional stability parameters include thermal stability (measured by differential scanning calorimetry), storage stability (assessing activity and aggregation state under different temperature and time conditions), and freeze-thaw stability. These data not only guide the proper storage and use of experimental samples but also provide important references for subsequent drug development. It is generally recommended to aliquot SHPS1 recombinant protein and store it at -80°C to avoid repeated freeze-thaw cycles. Before use, gel filtration or other methods should be employed to remove potential aggregates.

Applications of SHPS1 Recombinant Protein in Research

As an important research tool, SHPS1 recombinant protein plays an irreplaceable role in basic research and drug development. In molecular interaction studies, SHPS1 recombinant protein is widely used to identify and characterize its interactions with various ligands. The most typical example is the study of the SHPS1-CD47 interaction. Using techniques such as surface plasmon resonance (SPR), bio-layer interferometry (BLI), and isothermal titration calorimetry (ITC), scientists have precisely measured the kinetic and thermodynamic parameters of this interaction, finding that its dissociation constant (Kd) is at the nanomolar level, indicating a high affinity between the two. These studies not only reveal the structural basis of the SHPS1-CD47 signaling axis but also provide a theoretical foundation for developing drugs targeting this interaction.

In cell signal transduction research, SHPS1 recombinant protein also plays a key role. Researchers use immobilized SHPS1 extracellular domain protein to stimulate cells, specifically activating downstream signaling pathways without interference from other receptors, thereby clarifying the SHPS1-mediated signaling network. By combining phosphorylation-specific antibodies and mass spectrometry, scientists have identified multiple SHPS1-regulated signaling pathways, including SHP-1/SHP-2-dependent inhibitory signaling pathways and integrin-related cell adhesion pathways. Particularly interesting is the recent discovery that SHPS1 signaling exhibits significant cell-type specificity. In neurons, it primarily participates in synaptic plasticity regulation, while in immune cells, it mainly regulates phagocytosis and inflammatory responses. These findings largely rely on the application of various SHPS1 recombinant protein tools.

SHPS1 recombinant protein also holds significant value in drug screening and development. High-throughput drug screening platforms based on SHPS1 have helped discover multiple lead compounds that can modulate the interaction between SHPS1 and CD47 or other ligands. For example, some small-molecule inhibitors can specifically block SHPS1-CD47 binding, thereby disrupting the "don't eat me" signal and enhancing macrophage-mediated tumor cell killing. Additionally, SHPS1 recombinant protein has been used as an immunogen to prepare antibody drugs. Several monoclonal antibodies with therapeutic potential have entered preclinical or clinical research stages. Some of these antibodies are antagonistic, designed to block SHPS1's immunosuppressive function, while others are agonistic, aimed at enhancing SHPS1's inhibitory signals to treat autoimmune diseases.

It is worth mentioning that SHPS1 recombinant protein also has potential applications in diagnostic reagent development. Studies have shown that in certain disease states (such as tumors or neurodegenerative diseases), the levels or glycosylation patterns of SHPS1 in patient body fluids undergo characteristic changes. Therefore, standardized detection methods based on SHPS1 recombinant protein may serve as novel diagnostic markers. For example, comparing the binding characteristics of patient serum samples with SHPS1 recombinant protein could lead to the development of new methods for early tumor screening.

Challenges and Future Directions

Despite significant progress in SHPS1 recombinant protein research, many challenges remain on the path to clinical application. A major obstacle is the delivery of protein drugs. As SHPS1 is a large membrane protein, its in vivo delivery efficiency is limited, making it difficult to effectively reach target tissues. Current strategies under exploration include developing novel delivery systems (such as liposomes or exosome encapsulation), designing smaller functional fragments (such as SHPS1 variants in nanobody form), and optimizing administration routes (such as local injection or targeted modification). Another challenge is production costs. While mammalian cell expression systems can provide high-quality SHPS1 recombinant protein, they are expensive and have limited yields. This has prompted researchers to develop more economical expression systems or improve existing production processes.

From a technological development perspective, there are several noteworthy directions for SHPS1 recombinant protein research. The first is engineered modification, where rationally designed or directed evolution techniques are used to develop SHPS1 variants with improved properties, such as enhanced stability, increased affinity, or new functionalities. The second is the development of multifunctional fusion proteins, combining SHPS1 with other functional domains (such as cytokines, targeting modules, or detection tags) to create therapeutic agents or diagnostic tools with multiple functions. Another important direction is the application of glycoengineering technology in SHPS1 recombinant protein production, where precise control of glycosylation patterns can optimize its pharmacodynamic and pharmacokinetic properties.

In the coming years, with a deeper understanding of SHPS1's biological functions and advancements in protein engineering, SHPS1 recombinant protein is expected to play an even greater role in the biomedical field. From basic research tools to clinical therapeutics, from in vitro diagnostic reagents to in vivo imaging probes, the versatility of SHPS1 recombinant protein will provide new ideas and methods for the diagnosis and treatment of various diseases. Particularly in the context of personalized and precision medicine, tailored SHPS1 recombinant protein treatment plans for specific patients may become a reality. As more clinical trials are conducted, SHPS1 recombinant protein is poised to move from the laboratory to the clinic, making significant contributions to human health.

Click on the product catalog numbers below to access detailed information on our official website.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.